Full-Time
Executive Director
Pipeline and Business Development Valuation
Posted on 9/3/2025
BeOne
1,001-5,000 employees
Global oncology therapeutics discovery, development, manufacturing
Compensation Overview
$215.4k - $295.4k/yr
No H1B Sponsorship
Remote in USA
Remote
Candidate must reside within the US.
 Business & Strategy (1) |
|---|
- Advanced degrees in life sciences and/or business
- MS Degree with a minimum of 10 plus years of relevant experience in commercial assessment/new product planning/disease area strategy/early commercialization from the pharmaceutical industry, consulting, or equity analyst roles
- Oncology and Immunology & inflammatory disease area knowledge/experience strongly preferred
- Proficient in both primary and secondary market research
- Demonstrated track-record in indication-, and patient-level forecasting methodologies
- Excellent communication skills and strong analytical skills required to analyze scientific and financial data, synthesize insights and stories behind the data, and prepare precise as well as concise presentations for senior executives’ review
- Experience of working in a cross-functional setting
- Ability to work on multiple projects simultaneously and effectively prioritize work
- Ability to work in a rapidly changing environment
- Excellent learning capability and aspiration for excellence
- Lead pipeline commercial assessment across all therapeutic areas and development stages for enterprise planning and annual LRP purposes
- Support commercial assessments through appropriate insight generation and subsequent quantification of the opportunity, with clear articulation of key assumptions / value drivers / risk parameters
- Engage with key stakeholders across R&D and commercial teams to ensure visibility of key assumptions and resulting project-related forecasts
- Develop strong working relationships with key partners such as Pricing/Access, GCSO franchise teams, CBDI and GPPM to ensure cross-functional perspectives are incorporated within commercial assessments
- Develop portfolio-level view of BeOne pipeline to ensure thorough understanding of the impact upon commercial assessments arising from overlapping development plans, or through cannibalization of later lines of therapy as asset LCM plans move into earlier treatment settings
- Drive quantitative and support qualitative commercial input at both the indication and program levels to inform portfolio prioritization
- Collaborate with GPPM to develop informative and effective multidisciplinary portfolio prioritization framework and process
- Support the commercial and business case assessments for major pipeline investment decisions at the BPRC level and to inform go-no-go decisions at DRC, ERC, and program team levels
- Partner with both global commercial franchise teams and BD to support commercial assessment for global business development activities, covering all deal types and targets/assets at all development stages
- Inform and influence TPP/CDP development, Disease Area Strategies and asset-level strategy formulation by synthesizing insights from primary market research, treatment/competitive landscape monitoring and commercial assessment-based analytics
- Manage budget, AOP and LRP for the full team
- Oncology and Immunology & inflammatory disease area knowledge/experience strongly preferred
BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dongcheng District, China
Founded
2010
Simplify's Take
What believers are saying
- TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
- Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
- First GAAP profitability achieved in 2025 with $942M free cash flow generation.
What critics are saying
- AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
- Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
- Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.
What makes BeOne unique
- BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
- Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
- Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Wellness Program
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 5%Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.
BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.
BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.
BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.
BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...